A Study of LY4268989 (MORF-057) in Healthy Participants
Completed · Phase 1 · NCT06964776
Conditions: Healthy
At a glance
- Research payments reported, 2025
- $3.2M
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 144
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY4268989 (drug), Placebo (drug), Midazolam (drug), Midazolam (drug)
- Dates
- Started 2025-05-01; completion 2026-02-17
- Results posted
- Not yet
The purpose of this study is to measure the body's absorption and processing of the study drug, the study drug's effect on the body, safety, and tolerability with LY4268989 (MORF-57) in healthy participants, including Japanese and Chinese participants
From ClinicalTrials.gov, last updated 2026-03-27. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $3.2M in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Anaheim Clinical Trials LLC $3.2M
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.